Abstract:Parvovirus B19 frequently infects children and targets cells of the erythroid lineage. Although healthy children rarely suffer severe disease, children with sickle cell disease (SCD) can experience transient red cell aplasia (TRCA), hospitalization, and life-threatening anemia upon first virus exposure. Given that children with SCD can also suffer chronic inflammation and that parvovirus B19 has been associated with autoimmune disease in other patient populations, we asked if parvovirus B19 infections contributed to acute and chronic immune abnormalities in children with SCD. Nineteen hospitalized patients with SCD and parvovirus B19–induced TRCA were evaluated. Blood tests included CBC, flow cytometry, and total antibody isotype analyses. Cytokine/chemokine analyses were performed on nasal wash (NW) samples, representing a common site of viral entry. Unusually high white blood cell count (WBC) and absolute neutrophil count (ANC) values were observed in some patients. A correlation matrix with Day 0 values from the 19 patients then identified two mutually exclusive phenotype clusters. Cluster 1 included WBC, ANC, absolute reticulocyte count (ARC), absolute lymphocyte count (ALC), lactate dehydrogenase (LDH), NW cytokines/chemokines, % naïve cells among B cell and T cell populations, and parvovirus-specific IgG. This cluster was negatively associated with virus load, suggesting a signature of successful adaptive immunity and virus control. Cluster 2 included virus load, % CD38+CD24− cells among CD19+ B cells (termed 'plasmablasts' for simplicity), % HLA-DRlow cells among CD19+ B cells, IgG4, and % memory phenotypes among B cell and T cell populations. Plasmablast percentages correlated negatively with parvovirus-specific IgG, possibly reflecting a non-specific trigger of cell activation. All patients were released from the hospital within 1 week after admission, and the highest WBC and ANC values were eventually reduced. Nonetheless, a concern remained that the acutely abnormal immune profiles caused by parvovirus B19 infections could exacerbate chronic inflammation in some patients. To avoid the numerous sequelae known to affect patients with SCD following hospitalizations with parvovirus B19, rapid development of a parvovirus B19 vaccine is warranted.

Rheumatic manifestations and sequela of acute parvovirus B19 infection in hospitalized adult population

High risk of misclassification of acute Parvovirus B19 infection into a systemic rheumatic disease

Erythema nodosum manifestation of Parvovirus B19-associated reactive arthritis

Parvovirus B19 in Rheumatic Diseases

[Parvovirus B19 infections in adults]

Parvovirus B19 infection and systemic lupus erythematosus: Activation of an aberrant pathway?

The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease

Frequency and significance of parvovirus B19 infection in patients with rheumatoid arthritis

Parvovirus B19 and immune disorders

Immune Cell Profiles of Patients with Sickle Cell Disease during Parvovirus B19–Induced Transient Red Cell Aplasia

Emerging lupus-like manifestations in acute parvovirus B19 infection

Does parvovirus infection have a role in systemic lupus erythematosus?

The Relation Between the Parvovirus B19 and Pregnancy

Parvovirus B19 induced lupus-like syndrome with nephritis

Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy

Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19

Human parvovirus B19 and autoimmune diseases. Review of the literature and pathophysiological hypotheses

Pericarditis and pleuritis associated with human parvovirus B19 infection in a systemic lupus erythematosus patient

Frequency of antiparvovirus B19 antibodies in rheumatoid arthritis and systemic lupus erythematosus

Neurological aspects of human parvovirus B19 infection: a systematic review

Human parvovirus B19-induced acute glomerulonephritis: a case report